AzTrials
AzTrials

Endometrial CancerNCT07435623

Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study

An observational study of Endometrial Cancer and Cervix Cancer, run by Tata Memorial Hospital at 1 site in India.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Read more about this study

Who is it for?
Ages 18 to 75 years, women only
Conditions the study is for
Endometrial Cancer, Cervix Cancer
How many people
300 participants
Where
1 siteIndia
Study dates
10 May 2025to 25 Aug 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Annually 40-50 patients of post-operative cervix and post-operative endometrial cancer which are treated with adjuvant radiotherapy (with or without chemotherapy) and/or Brachytherapy are seen by gynaecological services. So, assuming 40-50 patients per year we expect this 3-year study to have up to 300 patients

Who may be able to join

  • Patients more than 18 years of age at the time of diagnosis.
  • All patients with confirmed histological diagnosis of cervical or endometrial cancer.
  • Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and/or brachytherapy at TMH/ACTREC will be included.
  • Patients whose follow up information available

Who cannot join

  • Patients with incomplete treatment details.
  • Patient having residual disease post-surgery.
  • Patient treated for post-operative recurrences.
  • Patient who lost to follow up.
  • Patients with Immunosuppressive disorder

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Supriya Chopra contact

02227405000 ext. 5113

supriyasastri@gmail.com

India1 site, 1 recruiting

  • Tata Memorial Center

    Mumbai, Maharashtra, 400012

    Supriya sastri (Chopra), MD, 022-68735000 ext. 5113, supriyasastri@gmail.com

    Supriya Sastri (Chopra), MD

    Recruiting

Other trials in India

About this study

Official title: Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Requiring Postoperative IMRT and/or Brachytherapy

Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Treatment of early stage cervical cancer (Stage IB1-IIA) includes chemo-radiation or surgery +/- adjuvant (CT)RT and VBT if indicated. The choice of adjuvant treatment relies on identifying specific risk factors. Patients fulfilling Sedli's intermediate-risk criteria, requires pelvic radiotherapy alone and patients with high-risk Peter's criteria, require adjuvant chemoradiation. This risk-based approach helps tailor adjuvant therapies to individual patient.

India reported 16,413 new cases and 6,385 deaths of endometrial cancer, with a mortality rate of 0.73%. The primary treatment for endometrial carcinoma is total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). The Adjuvant treatment depends on risk stratification group according to ESGO/ESTRO/ESP guidelines determined through molecular-based risk stratification. Adjuvant treatment includes radiotherapy, chemotherapy, and brachytherapy.

Read more

To reduce the burden of acute and late toxicity, advanced external radiation techniques like image guided intensity modulated radiotherapy (IG IMRT) are used. IG IMRT have shown their potential to reduce late toxicity in long term survivors compared to 3DCRT technique. Since January 2020, our institution (TATA memorial centre, Mumbai) has incorporated routine IG-IMRT (Image-Guided Intensity-Modulated Radiation Therapy) for treatment of cervical and endometrial cancer. However, no post-implementation assessment of treatment outcomes and potential toxicity has occurred. This is retrospective observational study aims to evaluate the clinical application of IG-IMRT.

Primary aim of this study is to audit the 3 years incidence of ≥ grade II Gastrointestinal \& Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) between January 2020 to June 2023

Keywords
Cervical Cancer, Endometrical Cancer ,Gastrointestinal & Genitourinary toxicities
Medical subject headings
Endometrial Neoplasms, Uterine Cervical Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 3 years incidence of ≥ grade II Gastrointestinal & Genitourinary toxicities

    To audit the 3 years incidence of ≥ grade II Gastrointestinal \& Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) for cervical and endometrial cancer between January 2020 to December 2023

    Measured: 3 years

Secondary outcomes (5)

  1. Report acute toxicity in patients receiving adjuvant RT

    To report acute toxicity in patients receiving adjuvant RT from the time of treatment completion till 3 years

    Measured: 3 years

  2. Assess disease free and overall survival (for cervix and endometrial cancer separately).

    To assess 3-year disease free and overall survival (for cervix and endometrial cancer separately) from the time of treatment completion to 3 years

    Measured: 3 Years

  3. Assess local regional control

    To assess 3 years local regional control from the time of treatment completion till 3 years

    Measured: 3 Years

  4. Report dose-volume parameters for prediction of late grades II-IV gastrointestinal and genitourinary toxicity

    Report dose-volume parameters for prediction of late grades II-IV gastrointestinal and genitourinary toxicity from treatment completion till 3 years

    Measured: 3 Years

  5. compare outcomes with ongoing and completed institutional postoperative IMRT trials

    To compare outcomes with ongoing and completed institutional postoperative IMRT trials from the time of treatment completion to 3 years

    Measured: 3 Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2026
  2. Study start10 May 2025
  3. Primary completion10 Jul 2025
  4. Study completion25 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07435623
Sponsor's protocol ID
4454
Status last verified
Feb 2026
First submitted
20 Feb 2026
Last updated
2 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13. doi: 10.1200/JCO.2000.18.8.1606.

    PubMed 10764420

  • Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999 May;73(2):177-83. doi: 10.1006/gyno.1999.5387.

    PubMed 10329031

  • Chopra S, Dora T, Chinnachamy AN, Thomas B, Kannan S, Engineer R, Mahantshetty U, Phurailatpam R, Paul SN, Shrivastava SK. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):630-5. doi: 10.1016/j.ijrobp.2013.11.214.

    PubMed 24521678

  • Vandecasteele K, Tummers P, Makar A, van Eijkeren M, Delrue L, Denys H, Lambert B, Beerens AS, Van den Broecke R, Lambein K, Fonteyne V, De Meerleer G. Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):408-14. doi: 10.1016/j.ijrobp.2011.12.020. Epub 2012 Feb 28.

    PubMed 22377596

  • Chopra S, Gupta S, Kannan S, Dora T, Engineer R, Mangaj A, Maheshwari A, Shylasree TS, Ghosh J, Paul SN, Phurailatpam R, Charnalia M, Alone M, Swamidas J, Mahantshetty U, Deodhar K, Kerkar R, Shrivastava SK. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. J Clin Oncol. 2021 Nov 20;39(33):3682-3692. doi: 10.1200/JCO.20.02530. Epub 2021 Sep 10.

    PubMed 34506246

  • Wortman BG, Creutzberg CL, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

    PubMed 30356126

  • Correction to Lancet Oncol 2018; 19: 295-309. Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016/S1470-2045(18)30212-2. No abstract available.

    PubMed 29611526

  • de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jurgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12.

    PubMed 29449189

  • Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T; Radiation Therapy Oncology Group. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73. doi: 10.1016/j.ijrobp.2003.10.019.

    PubMed 15093913

  • Scotti V, Borghesi S, Meattini I, Saieva C, Rossi F, Petrucci A, Galardi A, Livi L, Agresti B, Fambrini M, Marchionni M, Biti G. Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer. 2010 Dec;20(9):1540-8. doi: 10.1111/IGC.0b013e3181f8fa26.

    PubMed 21370597

  • Creutzberg CL, Nout RA, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras E, van de Poll-Franse LV, van Putten WL; PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8. doi: 10.1016/j.ijrobp.2011.04.013. Epub 2011 Jun 2.

    PubMed 21640520

  • Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger NPB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LCHW, Brooks S, Jurgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, Verhoeven-Adema KW, Smit VTHBM, Putter H, Creutzberg CL. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986. doi: 10.1016/j.ijrobp.2020.10.030. Epub 2020 Oct 28.

    PubMed 33129910

  • Mohanty SK, Chopra S, Mudaliar A, Kannan S, Mahantshetty U, Engineer R, Ghosh J, Bajpai J, Gupta S, Shrivastava S. A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer. Indian J Cancer. 2018 Oct-Dec;55(4):327-335. doi: 10.4103/ijc.IJC_453_17.

    PubMed 30829265

  • Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018 Aug 20;36(24):2538-2544. doi: 10.1200/JCO.2017.77.4273. Epub 2018 Jul 10.

    PubMed 29989857

  • Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Bruner DW, Kachnic LA. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. J Clin Oncol. 2020 May 20;38(15):1685-1692. doi: 10.1200/JCO.19.02381. Epub 2020 Feb 19.

    PubMed 32073955

Questions about this trial

What is this clinical trial studying?

An observational study of Endometrial Cancer and Cervix Cancer, run by Tata Memorial Hospital at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Supriya Chopra (02227405000 ext. 5113, supriyasastri@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

3 years incidence of ≥ grade II Gastrointestinal & Genitourinary toxicities (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07435623, which also lists 31 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in